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Background: Chronic Obstructive Pulmonary Disease (COPD) is characterised by complex inflammatory, neuronal
and fibrotic changes. Brain-derived Neurotrophic Factor (BDNF) is a key regulator of neuronal plasticity, whereas
Transforming Growth Factor-β1 (TGF-β1) plays a crucial role in tissue repair and emphysema pathogenesis. Both
mediators are stored in platelets and released from platelets in inflammatory conditions and during serum
preparation. In patients with asthma, it was previously shown that elevated serum BDNF concentrations correlate
with disease severity, whereas TGF-β1 concentrations were normal.
Methods: In the present study, 63 patients with stable COPD (spirometric GOLD stages 2–4) and 17 age- and
comorbidity-matched controls were studied. Lung function, smoking history, medication, platelet concentrations in
peripheral blood and serum concentrations of BDNF, TGF-β1 and Serotonin (5-HT) were assessed in all participants.
Results: Serum levels of both BDNF and TGF-β1 (but not concentrations of platelets in peripheral blood) were
significantly elevated in all stages of COPD as compared to controls. Highest BDNF concentrations were found in
spirometric GOLD stage 3, whereas highest TGF-β1 serum levels were found in spirometric GOLD stage 4. There
were specific, stage-dependent correlations of these mediators with lung function parameters of the patients.
Conclusions: Taken together, we show that, in contrast to asthma, COPD is characterised by elevated
concentrations of both BDNF and TGF-β1 in serum. The stage-dependent association with lung function supports
the hypothesis that these platelet mediators may play a role in the pathogenesis of COPD.
Keywords: COPD, Inflammation, Fibrosis, BDNF, TGF-β1Background
Chronic obstructive pulmonary disease (COPD), a major
cause of morbidity and mortality worldwide [1], is char-
acterised by airflow limitation, predominantly in the
small airways, and the development of emphysema [2].
The underlying abnormality is an ill defined, chronic in-
flammatory process leading to remodeling of the airway
and alveolar walls [2,3]. In addition, systemic changes
play an important role in the pathogenesis of the disease
[4]. The complex fibrotic and neuromuscular changes in
COPD are in part different from those changes observed
in patients with asthma [5]. Current pharmacotherapy of
COPD has only limited impact on airway and alveolar
remodeling. Therefore, it is essential to better* Correspondence: paul.stoll@med.uni-rostock.de
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reproduction in any medium, provided the orunderstand the mechanisms of tissue remodeling in this
devastating disease [5].
A pilot study examining serum concentrations of 92
inflammation-associated analytes suggested that Brain–
derived neurotrophic factor (BDNF) is among the three
most highly elevated mediators in COPD [6]. Further-
more, a microarray analysis of 143 serum analytes postu-
lated that BDNF is the strongest predictor of reduced
FEV1 in COPD [7]. The precise function and regulation
of BDNF in COPD, however, has yet to be elucidated.
BDNF, a key mediator of neuronal plasticity in the adult,
has been shown to play a crucial role in acute and
chronic inflammatory conditions of the airways. BDNF
induces neuronal hyperreactivity leading to airway
hyperresponsiveness and cough [8,9] and increases the
number and function of airway smooth muscle cells
[10]. BDNF is stored in large amounts in platelets and is
released from platelets during platelet activation, such as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The majority (> 95%) of circulating BDNF is stored in
alpha granules of the platelets, together with Transform-
ing Growth Factor-β1 (TGF-β1). TGF-β1 has been
reported to play a major role in the pathogenesis of fi-
brosis and emphysema in COPD [11,12].
In patients with allergic asthma, serum and platelet
concentrations of BDNF are elevated as compared with
healthy controls, and correlate with airway obstruction
and airway hyperresponsiveness [9]. Although BDNF
and TGF-β1 are stored in the same platelet granule,
serum TGF-β1 concentrations are not significantly dif-
ferent from controls in patients with mild to moderate
asthma [9]. In contrast, a detailed investigation of the
concentrations of BDNF and other platelet-derived med-
iators in patients with COPD, and their relationship to
lung function and disease severity, is currently lacking. It
was the aim of the present study, therefore, to investi-
gate serum concentrations of BDNF and other platelet-
derived mediators and lung function in patients with
different stages of COPD and in non-COPD controls.
We hypothesised that the expression of BDNF and TGF-β1




All participants were recruited at a German rehabilita-
tion centre from February through September 2011.
Sixty-three patients with an already established diagnosis
of COPD were recruited. Inclusion criteria were as fol-
lows: (1) a history of active or passive tobacco smoking,
(2) a ratio of post-bronchodilator forced expiratory vol-
ume in one second (FEV1) to forced vital capacity (FVC)
of < 70 %, and (3) an increase of less than 10% of FEV1
following inhalation of 400 μg of salbutamol. Exclusion
criteria were: (1) acute exacerbations of COPD or acute
infections in the last 4 weeks prior to exclusion, (2)
other chronic inflammatory or autoimmune conditions,
(3) any malignant disorder and (4) treatment with clopi-
dogrel. The latter exclusion criterium was chosen be-
cause clopidogrel treatment, but not aspirin treatment,
inhibits the release of BDNF from human platelets and
has, therefore, an impact on BDNF serum levels in
humans [13]. For the classification of disease severity,
spirometric GOLD stages were used [1]. Seventeen
patients matched for age and comorbidities with a his-
tory of tobacco smoke inhalation but without clinical
signs consistent with COPD were enrolled as a control
group. Inclusion criteria for controls were (1) a history
of active or passive tobacco smoking, (2) a ratio of post-
bronchodilator forced expiratory volume in one second
(FEV1) to forced vital capacity (FVC) of > 70 %. Exclu-
sion criteria for controls were (1) any chronicinflammatory or autoimmune conditions, (2) any malig-
nant disorder and (3) treatment with clopidogrel. All
patients and controls provided their written informed
consent prior to enrollment. The study was approved by
the local Ethics committee of Rostock, Germany.
Measurements of laboratory parameters and lung
function
Peripheral blood was drawn from a cubital vein of the
participants. Serum samples were prepared by resting
the collected blood in additive-free containers for 60
minutes at room temperature (to ensure complete clot-
ting and platelet degranulation in the sample), followed
by centrifugation at 2000 x g for 15 minutes at room
temperature. Aliquots of serum samples were stored at
– 20° C until measurement. Serum concentrations of
BDNF and TGF-β1 were measured by ELISA as
described [14]. Serum levels of Serotonin (5-Hydroxy-
triptamine, 5-HT) were measured by High Performance
Liquid Chromatography (HPLC) as described [14]. Total
and differential blood cell counts were measured using
EDTA-containers as described [14]. Lung function para-
meters were assessed using a body plethysmograph (Car-
eFusion, Hoechberg, Germany) as described [9].
Statistical analysis
Statistical analysis was performed using SPSS Statistics
17.0 (SPSS Inc., Chicago, Illinois, USA). The majority of
parameters were not normally distributed. Therefore,
parameters were expressed as medians (minimum –
maximum). General differences in BDNF, Serotonin and
TGF-β1 concentrations between the groups were ana-
lysed using the Kruskal-Wallis test. For direct compari-
sons of specific groups, the Mann–Whitney-U test for
unrelated samples was used. For the analysis of trends in
BDNF, Serotonin and TGF-β1 concentrations, the
Jonkheere-Terpstra test was performed. In order to ex-
plore possible influencing factors for the observed differ-
ences in BDNF and TGF-ß1 concentrations in serum,
the following parameters, which showed at least a mild
correlation (r > 0.3) in an univariate analysis with BDNF
or TGF-ß1 concentrations in serum, were enrolled into a
multivariate analysis: BDNF concentration in serum,
TGF-ß1 concentration in serum, Serotonin concentra-
tion in serum, FEV1, platelet concentration in peripheral
blood, body mass index (BMI). Correlation analyses were
performed using Spearman’s correlation coefficient.
Probability values of p<0.05 were regarded as significant.
Results
Characteristics of the participants
The clinical characteristics of the different groups are
detailed in Table 1. A total of 63 patients (female: n=24,
male: n=39) with COPD (22 patients with spirometric
Table 1 Participants characteristics
COPD Control p
all GOLD 2 GOLD 3 GOLD 4 COPD
(all) vs.
Control
n = 63 n = 22 n = 28 n = 13 n = 17
Age 64.0 67.0 63.0 62.0 62.0 0.96
(years) [43. . .79] [45. . .78] [43. . .76] [51. . .79] [51. . .73]
Body Mass Index 24.8 29.4 23.4 23.8 27.4 0.40
(kg*m-2) [13.6. . .46.5] [19.3. . .39.7] [13.6. . .46.5] [15.8. . .32.0] [22.9. . .57.1]
pack years 40.0 41.5 42.0 34.0 25.0 < 0.001
[0. . .100] [0. . .100] [18. . .75] [20. . .60] [20. . .40]
Smoking history -
never/active/former 2 / 11 / 48 1 / 6 / 14 1 / 5 / 21 0 / 0 / 13 0 / 1 / 16
Inhaled medication -
LABA/LAMA/ICS 59 / 58 / 49 21 / 19 / 20 25 / 26 / 18 13 / 13 / 11 0 / 0 / 0
Oral medication -
OCS/PDE-I/TPH 13 / 5 / 10 3 / 0 / 2 7 / 2 / 5 3 / 3 / 3 0 / 0 / 0
Hemoglobin 14.4 14.3 14.7 13.8 11.6 < 0.001
(mg/l) [10.3. . .16.9] [10.3. . .16.4] [10.4. . .16.9] [11.6. . .16.8] [9.6. . .14.8]
Hematocrit 42.4 42.4 42.8 42.0 35.7 < 0.001
(%) [31.1. . .49.9] [31.1. . .47.4] [31.1. . .49.9] [37.6. . .49.4] [27.8. . .41.6]
Platelets 292 239 322 293 289 0.56
(*109/l) [145. . .787] [172. . .417] [154. . .787] [145. . .504] [177. . .569]
Leukocytes 8.6 8.1 9.4 8.7 8.7 0.69
(*109/l) [6.1. . .18.3] [6.2. . .11.9] [6.1. . .18.3] [6.8. . .17.8] [6.4. . .11.6]
FEV1 total 1.13 1.46 1.11 0.69 2.32 < 0.001
(l) [0.45. . .2.34] [0.96. . .2.34] [0.76. . .1.76] [0.45. . .0.91] [1.33. . .4.24]
FEV1 % pred. 42.6 58.2 41.1 27.4 76.1 < 0.001
(%) [16.3. . .76.2] [50.3. . .76.2] [30.0. . .48.5] [16.3. . .29.7] [55.2. . .145.8]
FEV1 % VC 46.9 57.8 45.3 34.5 83.3 < 0.001
(%) [22.2. . .67.0] [41.7. . .67.0] [30.2. . .63.8] [22.2. . .49.3] [71.0. . .99.7]
MEF25 total 0.25 0.31 0.25 0.17 1.02 < 0.001
(l/s) [0.10. . .0.62] [0.13. . .0.62] [0.12. . .0.38] [0.10. . .0.36] [0.36. . .4.58]
MEF25 % pred. 18.8 24.7 17.5 12.9 62.3 < 0.001
(%) [7.3. . .41.4] [10.9. . .41.4] [8.8. . .32.1] [7.3. . .30.0] [29.6. . .286.0]
RV total 4.46 3.62 4.76 6.05 2.60 < 0.001
(l) [2.27. . .8.48] [2.72. . .5.37] [2.27. . .8.48] [3.66. . .8.26] [1.12. . .3.76]
RV % pred. 200.6 158.5 203.6 273.7 113.9 < 0.001
(%) [101.9. . .376.8] [114.0. . .240.1] [101.9. . .376.8] [204.5. . .317.5] [48.1. . .146.8]
TLC total 7.09 6.17 7.21 8.46 5.40 < 0.01
(l) [4.1. . .14.09] [5.1. . .8.9] [4.1. . .11.7] [5.0.. . .14.1] [3.0. . .8.2]
TLC % pred. 116.8 111.1 116.8 135.8 84.5 < 0.001
(%) [71.5. . .179.2] [83.3. . .149.1] [71.5. . .169.5] [107.5. . .179.2] [52.3. . .111.0]
RV % TLC 64.8 57.4 65.2 73.5 50.1 < 0.001
(%) [45.1. . .86.2] [45.1. . .70.6] [52.3. . .73.6] [65.4. . .86.2] [26.5. . .63.5]
TLCO / VA total 0.69 0.84 0.64 0.37 1.03 < 0.001
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Table 1 Participants characteristics (Continued)
(mmol/min/kPa/l) [0.01. . .1.72] [0.37. . .1.72] [0.13. . .1.27] [0.01. . .0.90] [0.72. . .1.91]
TLCO / VA % pred. 49.0 60.3 42.3 27.8 77.6 < 0.001
(%) [0.95. . .105.4] [25.6. . .105.4] [8.0. . .89.1] [0.95. . .68.6] [57.3. . .138.5]
Data are shown as median [minimum. . .maximum]. LABA – long-acting beta agonist, LAMA – long acting muscarinic antagonist, ICD – inhaled corticosteroids,
OCS – oral corticosteroids, PDE-I – phosphodiesterase inbibitor, TPH – theophylline.
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3, and 13 patients with spirometric GOLD stage 4), and
17 comorbidity-matched controls (female: n=5, male:
n=12) were analysed. Of the 63 COPD patients, 59
(94%) were treated with long-acting β-agonists (LABA),
58 (92%) with long-acting muscarinic antagonists
(LAMA) and 49 (78%) with inhaled corticosteroids
(ICS). Thirteen patients (21%) were treated with oral
corticosteroids (OCS). Five patients (8 % of all partici-
pants) were treated with the PDE-4-inhibitor roflumilast.
Five patients (8 % of all patients) were taking antidepres-
sants: GOLD stage 2 sertraline (n=1) and opipramole
































Figure 1 Platelet counts and serum levels of platelet-derived mediato
BDNF (B), TGF-β1 (C) and Serotonin (D) in different stages of COPD (GOLD
interquartile range (edges of the box), the range of values that are not out
interquartile ranges from the upper or lower quartile: dots) are shown. Aste
values of p<0.05 were regarded as statistically significant.citaloprame (n=1) and doxepine (n=1). None of the
comorbidity-matched 17 controls was treated with either
of the aforementioned drugs (Tab. 1). There were no sig-
nificant differences in age or body mass index between
the groups (Tab. 1). Patients in all 3 COPD groups had
significantly more pack years than controls (Tab. 1). All
lung function parameters differed significantly between
controls and the 3 groups of patients with COPD (Tab.
1). All stages of COPD presented with significantly ele-
vated hemoglobin and hematocrit levels as compared to
non-COPD controls. In contrast, there were no differ-
ences in platelet or leukocyte counts between controls
























rs. The Figure shows platelet counts (A) and serum levels (ng/ml) of
II, GOLD III, GOLD IV) and in controls. The median (line within the box),
liers (vertical lines) and outliers (cases more distant than 1.5
risks mark significant differences between the groups. Probability
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COPD GOLD 2 (239 x 109 platelets/l) and GOLD 3 (322
x 109 platelets/l, p<0.05) (Figure 1A).
Serum concentrations of BDNF and other platelet-derived
mediators
The general analysis of serum mediators using the
Kruskal-Wallis test revealed that there were statistically
significant differences in BDNF and TGF-β1 serum con-
centrations, but not Serotonin serum concentrations, be-
tween controls and patients with COPD. Direct
comparisons between the groups showed that serum
concentrations of BDNF were significantly elevated in all
COPD subgroups compared to non-COPD controls
(Figure 1B). In contrast, there were no significant differ-
ences in serum BDNF concentrations between COPD
subgroups, although there were highest median serum
BDNF concentrations in spirometric GOLD stage 3
(Figure 1B). In order to relate the observed changes of
BDNF to other platelet-derived mediators, direct com-
parisons of the subgroups were performed for TGF-β1
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Figure 2 Correlation of platelet-derived mediators BDNF, TGF-β1 and
are correlations between serum levels (ng/ml) of BDNF and TGF-β1 for all C
serum levels (ng/ml) of BDNF and Serotonin for all COPD patients and con
calculated with SPSS (Chicago, Illinois, USA). Spearman’s rank correlation co
graph.Serotonin (5-Hydroxytryptamine, 5-HT, which is stored
in platelet dense-core granules). In patients with spiro-
metric GOLD stages 2 and 3, TGF-β1 serum levels were
significantly elevated compared to non-COPD controls
(Figure 1C). There were highest median TGF-β1 serum
levels (median: 53.9 ng/ml) in patients with spirometric
GOLD stage 4, but this was not significant (Figure 1C).
Due to the high variability of 5-HT serum concentra-
tions in patients with COPD, the only statistically signifi-
cant difference was found between controls and patients
with spirometric GOLD stage 3 (Figure 1D). The
Jonkheere-Terpstra test revealed that there was a trend
to increasing BDNF and TGF-β1 serum concentrations
(but not Serotonin serum concentrations) with increas-
ing COPD severity.
Serum concentrations of BDNF correlated significantly
with serum concentrations of TGF-β1, both in patients
with COPD and in controls (Figure 2). In contrast,
BDNF serum concentrations correlated with 5-HT
serum concentrations only in patients with COPD, but
not in controls (Figure 2). There were no significant dif-
ferences in serum levels of BDNF, TGF-β1 and SerotoninB
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Serotonin in COPD patients and controls. Shown in the upper line
OPD patients and controls. The lower line shows correlations between
trols. Each dot represents one patient; the line is the regression line
efficient (r) and the significance of the correlation (p) are given in the
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and those not treated with ICS (n=14) or OCS (n=50).
In addition, there were no significant differences in
BDNF, TGF-β1 and Serotonin serum levels between
patients treated with antidepressants (n=5) or roflumi-
last (n=5) and those not treated with antidepressants
(n=58) or roflumilast (n=58). The multivariate analysis
revealed that only TGF-ß1 in serum and Serotonin in
serum were significantly associated with serum BDNF
concentrations, and only BDNF in serum and platelet
counts were significantly associated with serum TGF-ß1
concentrations.
Correlation of platelet-derived mediators with lung
function
In the total group of patients with COPD, there was no
significant correlation between serum BDNF and FEV1
(% predicted), but a trend to a negative correlation be-
tween serum TGF-β1 and FEV1 (% predicted) (Figure 3).
In contrast, subgroup analysis revealed a negative correl-
ation between FEV1 and serum BDNF (r=−0.41, p<0.05),
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Figure 3 Correlation of serum BDNF and TGF-β1 with FEV1 (forced ex
the left column are correlations between serum levels of BDNF (ng/ml) and
(C). The right column shows correlations between serum levels of TGF-β1 (
stage GOLD III (D). Each dot represents one patient; the line is the regressio
correlation coefficient (r) and the significance of the correlation (p) are giveGOLD stage 3 (the largest subgroup of patients). In con-
trast, there were no correlations between FEV1 and
serum concentrations of 5-HT, neither in the group of
all COPD patients nor in one of the subgroups (Figure 4).
In addition, there were no significant correlations be-
tween TGF-β1 and emphysema markers (residual vol-
ume and carbon monoxide diffusion capacity), neither in
the total group of patients nor in the COPD subgroups
(data not shown).Discussion
There is growing evidence suggesting a crucial role of
neurotrophins such as BDNF in the pathogenesis of ob-
structive airway diseases [7,9,15]. In patients with aller-
gic asthma, a close relationship between elevated
systemic BDNF concentrations and lung function has
been demonstrated, whereas systemic TGF-β1 concen-
trations were normal [9,16]. This clinical study is the
first to show that, in contrast to asthma, COPD is char-
acterised by an elevation of both BDNF and TGF-β1 in
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spiratory volume in 1 second) in patients with COPD. Shown in
FEV1 for all COPD patients (A) and patients with COPD stage GOLD III
ng/ml) and FEV1 for all COPD patients (B) and patients with COPD
n line calculated with SPSS (Chicago, Illinois, USA). Spearman’s rank





























 r = - 0.18 






0.75 1.0 1.25 1.5 1.75 
 r = - 0.25 
p = 0.21 
Figure 4 Correlation of Serotonin (5-HT) with FEV1 (forced exspiratory volume in 1 second) in COPD patients. Shown are correlations
between serum levels of Serotonin (ng/ml) and FEV1 for all COPD patients and subjects with COPD stage GOLD III. Each dot represents one
patient; the line is the regression line calculated with SPSS (Chicago, Illinois, USA). Spearman’s rank correlation coefficient (r) and the significance
of the correlation (p) are given in the graph.
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tion in COPD.
BDNF and TGF-β1 are both stored in the alpha-
granules of human platelets and are released by de-
granulation after activation [17]. The neurotrophin
BDNF is a key mediator of neuronal and smooth muscle
plasticity [8-10], whereas TGF-β1 plays a major role in
the pathogenesis of connective tissue remodeling and fi-
brosis [11,12]. Altered platelet activity has been shown
both in patients with COPD [18] and in patients with
asthma [19], however, the regulation of platelet-derived
mediators in obstructive airway diseases is still incom-
pletely understood. It was previously shown that serum
and platelet concentrations of BDNF (but not TGF-β1)
are elevated in patients with mild to moderate allergic
asthma, correlating with airway obstruction and airway
hyperresponsiveness [9]. These clinical data confirmed
findings from animal models of allergic asthma, which
showed a crucial role of BDNF in the pathogenesis of
airway hyperresponsiveness and airway obstruction
[20,21]. Altered BDNF regulation may also contribute to
adverse effects of β2-agonists in asthma [22]. Salmeterol
monotherapy significantly increased systemic BDNF
concentrations in patients with asthma, and these
changes correlated with the deterioration of airway
hyperresponsiveness [16]. Increased BDNF concentra-
tions and increased airway hyperresponsiveness were
both reduced after concomitant therapy with fluticasone
[16] confirming previous data showing a suppression of
BDNF production by corticosteroids [9,23].
In the present study, a significant increase in BDNF
serum concentrations was also found in patients with
COPD. This finding is in line with experimental data
showing systemic overproduction of BDNF in a rat
model of COPD [24]. A recent study examining serumconcentrations of a broad panel of 92 inflammation-
associated analytes postulated that BDNF is among the
three most highly elevated mediators in COPD (CD40
Ligand, Epithelial Growth Factor, BDNF) [6]. The ana-
lysis of possible confounding factors for the increase in
BDNF concentrations in patients with COPD in our
study showed that (in addition to the diagnosis of
COPD) only platelet mediators significantly influenced
BDNF concentrations in serum. This finding confirms
the concept that BDNF in serum is derived from plate-
lets. Of note, there were no significant differences in
platelet concentrations between controls and patients
with COPD, indicating that elevated BDNF concentra-
tions in patients with COPD are not explained by nu-
meric differences in platelets in peripheral blood.
Instead, increased concentrations of BDNF in platelet
granules in patients with COPD appear to be the most
likely explanation for the observed elevation of serum
BDNF in COPD. However, platelet concentrations were
significantly higher in GOLD stage 3 as compared to
GOLD stage 2. Therefore, it cannot be excluded that the
trend to an increase of BDNF concentrations in GOLD
stage 3 (as compared to GOLD stage 2) might be
explained by an elevation of platelet concentrations in
peripheral blood.
The large majority of patients (94%), but none of the
controls examined in our study were treated with
LABAs. Thus, since therapy with the LABA salmeterol
was shown to increase BDNF concentrations in serum of
patients with asthma [16], it cannot be excluded that the
difference between patients and controls is attributable
to LABA therapy. However, several lines of evidence
suggest that LABA therapy is not the sole explanation
for elevated BDNF serum concentrations in patients
with COPD. First, a previous study in animals not
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BDNF in a model of COPD [24]. Secondly, in contrast
to patients with asthma [16], neither inhaled nor oral
corticosteroids had an impact on BDNF serum levels in
patients with COPD, suggesting that patients with
COPD and asthma might differ in their BDNF response
to treatment. Finally, LABA monotherapy is a safe first-
line therapeutic option in patients with COPD, whereas
LABA monotherapy is harmful in patients with asthma
[16]. Thus, the lack of detrimental effects of LABAs on
COPD control suggests that LABAs do not have the
same effect on systemic BDNF concentrations in
patients with COPD as in patients with asthma. Taken
together, we speculate that enhanced BDNF serum levels
observed in patients with COPD were not attributable to
pharmacological treatment, but represent a genuine
characteristic of this disease.
There is growing evidence from animal models that
antidepressants [25] and inhibitors of the phosphopdies-
terase 4 (PDE-4) [26,27] can increase BDNF production.
In addition, corticosteroids have been postulated to de-
crease BDNF production [9,23]. In contrast to the con-
trols, a small fraction of patients with COPD was treated
with antidepressants (8%), roflumilast (8%) or oral corti-
costeroids (21%). Although we did not find significant
differences in BDNF concentrations between patients
treated with antidepressants, roflumilast or oral corticos-
teroids and those patients not treated with these drugs,
our study was clearly underpowered to draw any firm
conclusions on the influence of different classes of anti-
depressants, roflumilast or oral corticosteroids on BDNF
serum concentrations in patients with COPD. Further
studies with higher percentages of patients with COPD
treated with antidepressants, roflumilast or oral corticos-
teroids are needed to explore this issue.
In contrast to patients with asthma, highest BDNF
concentrations were not found in patients with most se-
vere disease. Instead, highest BDNF concentrations were
found in patients with spirometric GOLD stage 3. Of
note, in this subgroup of patients, a significant negative
correlation between FEV1 and serum BDNF was found,
which was comparable to the findings in asthma [9].
The lacking association of serum BDNF with FEV1 in
the total group of patients with COPD could have 3 rea-
sons: (1) parameters of airflow limitation could be con-
founded by emphysema development, (2) the maximum
of BDNF production and BDNF effects could take place
in patients with less severe disease, and (3) BDNF serum
concentrations could be confounded by a concomitant
depressive disorder of the patients. Firstly, the reduction
in FEV1 in COPD is both due to airflow limitation and
due to the presence of emphysema. All patients with
spirometric GOLD stage 4 analysed in our study had a
residual volume (RV) > 200 % of the predicted value,suggesting that severe emphysema was a major deter-
minant of the observed FEV1 reduction in this subgroup.
In contrast, the RV was significantly lower in the sub-
group of patients with spirometric GOLD stage 3, which
implies that the relative contribution of airflow limita-
tion to the FEV1 reduction was higher in the group with
spirometric GOLD stage 3 than in the group with spiro-
metric GOLD stage 4. Thus, it might be speculated that
the disappearance of the association between BDNF and
FEV1 in spirometric GOLD stage 4 was due to a strong
influence of emphysema on the FEV1 reduction in this
subgroup. Secondly, it is conceivable that the BDNF pro-
duction and the subsequent BDNF effects on airflow
limitation are most pronounced in patients with spiro-
metric GOLD stage 3. It has been shown that mono-
nuclear cells (such as lymphocytes and monocytes) are
important sources of BDNF in inflammatory conditions
[9]. Of note, the number of lymphoid follicles in airway
walls (which are important markers of small-airway in-
flammation in COPD) peaks in spirometric GOLD stage
3 [28]. Thus, it is conceivable that BDNF might play a
major role in lung function reduction in COPD in those
patients with most severe small-airway inflammation
(which are not necessarily those patients with most se-
vere FEV1 reduction). Finally, depression, which is com-
mon in patients with severe COPD [29], could reduce
BDNF serum concentrations in patients with severe
COPD. There is strong evidence from the literature indi-
cating that depression reduces serum BDNF concentra-
tions in humans [25]. Thus, concomitant depression
could mask a possible inflammatory BDNF overproduc-
tion in patients with severe COPD. This study was not
designed to investigate the association of BDNF levels
and the prevalence of depressive disorders in specific
stages of COPD. Therefore, future studies focusing on
this particular issue are warranted.
In contrast to patients with allergic asthma, there was
an increase in TGF-β1 concentrations in patients with
COPD. In addition, there was a correlation of BDNF
with TGF-β1 in these patients, which was not found in
patients with asthma [9]. Thus, it appears that, in con-
trast to asthma, COPD is characterised by a concomitant
increase of both platelet-mediators BDNF and TGF-β1.
However, there were also stage-dependent differences
between the mediators: median serum BDNF concentra-
tions peaked in patients with spirometric GOLD stage 3,
whereas highest median concentrations of TGF-β1 were
found in patients with spirometric GOLD stage 4. TGF-
β1 has a multitude of effects in the organism. One of
them is an immunosuppressive effect on humoral (such
as inhibition of interleukin-2 production) and cellular
(such as inhibition of proliferation and differentiation of
T-cells) components of the immune system [11]. In
addition to the anti-inflammatory effect, TGF-β1 is a
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position of collagen [30]. In patients with COPD,
increased expression of TGF-β1 in the airway epithelium
has been associated with enhanced fibrotic airway re-
modeling [31]. Other reports postulated that increased
TGF-β1 expression in COPD is predominantly vessel-
associated [32]. In addition to TGF-β1 overproduction,
altered TGF-β1 signaling and several TGF-β1 poly-
morphisms have been postulated to play a role in the
pathogenesis of COPD and emphysema [33,34]. Our ob-
servation that median TGF-β1 serum concentrations
were rising with increasing disease severity supports the
postulate that this mediator plays a role in airway re-
modeling in COPD. However, we did not find a signifi-
cant association of TGF-β1 serum concentrations with
markers of emphysema (residual volume and the carbon
monoxide diffusion capacity), suggesting that the role of
TGF-β1 in the pathogenesis of structural changes in
COPD might be more complex.
In our study, a trend to elevated serum concentrations
of Serotonin (5-HT) was found in patients with COPD
as compared to controls. In patients with COPD in
spirometric GOLD stage 3, this elevation was statistically
significant. In a recently published study, plasma con-
centrations of serotonin (representing circulating sero-
tonin and not serotonin released from platelets after
serum preparation) were shown to be elevated in
patients with stable COPD [35]. In both studies (the pre-
vious study with plasma serotonin and our study with
serum serotonin), there was no significant association of
serotonin concentrations and lung function. Thus, it
might be hypothesized that there is an elevation of circu-
lating serotonin in stable COPD, but no elevation of
serotonin stored in platelets. In addition, the lacking as-
sociation with lung function might indicate that systemic
elevation of serotonin is a general phenomenon in
COPD, independent of disease severity. The source of
circulating serotonin in COPD, however, remains to be
elucidated [35].
There is an ongoing debate on similarities and differ-
ences between asthma and COPD [36]. The so-called
Dutch hypothesis postulates that both diseases have
common genetic characteristics, which are only modified
by different environmental stimuli, leading to a more
asthma-like or a more COPD-like phenotype [37]. Other
authors argue against this hypothesis, by stressing the
substantial differences in clinical presentation, pathology
and response to therapy between asthma and COPD
[38]. The results of the present study reveal both similia-
rities and differences between the diseases. On one hand,
both diseases were characterised by a systemic upregula-
tion of BDNF, a marker of neuromuscular dysfunction of
the airways. On the other hand, only COPD was asso-
ciated with a systemic upregulation of TGF-β1, a potentinductor of airway fibrosis and extracellular collagen de-
position. Thus, our study supports the idea that there
are both similarities and differences between the dis-
eases, which can be disentangled on a molecular level.
Conclusions
We demonstrate for the first time that, in contrast to
asthma, COPD is characterised by increased concentra-
tions of both BDNF and TGF-β1 in serum. The stage-
dependent association with lung function supports the
hypothesis that these platelet mediators may play a role
in the pathogenesis of COPD.
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